Suppr超能文献

SALL-4 和 Beta-Catenin 在鼻腔鼻窦胚胎性癌肉瘤中的表达。

SALL-4 and Beta-Catenin Expression in Sinonasal Teratocarcinosarcoma.

机构信息

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN, 37232-2561, USA.

Department of Otolaryngology - Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Head Neck Pathol. 2022 Mar;16(1):229-235. doi: 10.1007/s12105-021-01343-3. Epub 2021 Jun 9.

Abstract

Sinonasal teratocarcinosarcoma (SNTCS) is a rare, aggressive malignancy that displays a heterogeneous combination of malignant blastema-like, epithelial and mesenchymal components. Its exact histogenesis is unknown with hypotheses ranging from true germ cell derivation to origin from pluripotent stem cells. However, despite this tumor's multiphenotypic histology, which includes frequent glandular, squamous, and neuroectodermal differentiation similar to adnexal germ cell tumors, SNTCS appears to have some differences from adnexal teratomas. For example, unlike adnexal teratomas, SNTCS has never been described as a component in a mixed germ cell tumor. Accurate recognition of SNTCS is difficult due to its rarity and histologic overlap with other sinonasal tumors. It is even more problematic on biopsy, since not all elements may be present in small samples. SNTCS can also share similar staining patterns with other neoplasms in the differential diagnosis. A recent study found nuclear β-catenin expression in a single TCS, but this has yet to be confirmed in additional cases. SALL-4, a marker of germ cell tumors, has not been examined. We performed β-catenin and SALL-4 immunohistochemistry on whole sections of 7 SNTCS and 19 other sinonasal neoplasms to assess whether β-catenin and SALL-4 are of utility in establishing a diagnosis of SNTCS. Intensity of expression and percentage of staining was noted for each tumor. For SNTCS, distribution of staining within each histologic component (immature neuroectodermal, epithelial, and mesenchymal) was also documented. Nuclear β-catenin expression was not identified in any SNTCS, with all cases demonstrating membranous expression (6 cases) or cytoplasmic and membranous expression (1 case). SALL-4 immunohistochemistry, however, was relatively sensitive (85.7%) and specific (89.5%) for SNTCS. SALL-4 expression was also identified in one poorly differentiated neuroendocrine carcinoma and one case of sinonasal undifferentiated carcinoma. SALL-4 appears to have utility in distinguishing SNTCS from other high grade sinonasal tumors.

摘要

鼻窦胚胎性横纹肌肉瘤(SNTCS)是一种罕见的侵袭性恶性肿瘤,表现为恶性胚细胞瘤样、上皮和间叶成分的异质组合。其确切的组织发生尚不清楚,假说范围从真正的生殖细胞来源到多能干细胞起源。然而,尽管这种肿瘤具有多表型组织学,包括类似于附属生殖细胞肿瘤的频繁腺上皮、鳞状和神经外胚层分化,但 SNTCS 似乎与附属体腔瘤有一些不同。例如,与附属体腔瘤不同,SNTCS 从未被描述为混合生殖细胞瘤的组成部分。由于其罕见性和与其他鼻窦肿瘤的组织学重叠,准确识别 SNTCS 较为困难。在活检中问题更大,因为小样本中可能不存在所有成分。SNTCS 在鉴别诊断中也可能与其他肿瘤具有相似的染色模式。最近的一项研究发现单个 TCS 中存在核 β-连环蛋白表达,但这尚未在其他病例中得到证实。SALL-4,一种生殖细胞瘤的标志物,尚未被检查。我们对 7 例 SNTCS 和 19 例其他鼻窦肿瘤的全切片进行了β-连环蛋白和 SALL-4 免疫组织化学染色,以评估β-连环蛋白和 SALL-4 是否有助于建立 SNTCS 的诊断。注意了每个肿瘤的表达强度和染色百分比。对于 SNTCS,还记录了每个组织学成分(未成熟神经外胚层、上皮和间叶)内染色的分布。在任何 SNTCS 中均未发现核β-连环蛋白表达,所有病例均表现为膜表达(6 例)或细胞质和膜表达(1 例)。然而,SALL-4 免疫组织化学对 SNTCS 相对敏感(85.7%)和特异(89.5%)。SALL-4 表达也在 1 例低分化神经内分泌癌和 1 例鼻窦未分化癌中被识别。SALL-4 似乎有助于将 SNTCS 与其他高级别鼻窦肿瘤区分开来。

相似文献

1
SALL-4 and Beta-Catenin Expression in Sinonasal Teratocarcinosarcoma.
Head Neck Pathol. 2022 Mar;16(1):229-235. doi: 10.1007/s12105-021-01343-3. Epub 2021 Jun 9.
3
Teratocarcinosarcoma of the nasal cavity and paranasal sinuses: report of 3 cases with assessment for chromosome 12p status.
Hum Pathol. 2008 Apr;39(4):605-9. doi: 10.1016/j.humpath.2007.09.002. Epub 2008 Mar 4.
4
Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation.
Head Neck Pathol. 2009 Mar;3(1):31-6. doi: 10.1007/s12105-008-0094-x. Epub 2008 Dec 4.
5
Sinonasal teratocarcinosarcoma.
Am J Otolaryngol. 2010 Jul-Aug;31(4):300-3. doi: 10.1016/j.amjoto.2009.02.022. Epub 2009 May 19.
6
Sinonasal teratocarcinosarcoma: a clinical and pathological analysis.
Int J Surg Pathol. 2013 Feb;21(1):37-43. doi: 10.1177/1066896912457202. Epub 2012 Aug 24.
7
Sinonasal teratocarcinosarcoma: an unusual neoplasm.
Pathol Res Pract. 1995 Mar;191(2):166-71; discussion 172-3. doi: 10.1016/S0344-0338(11)80567-4.
8
A case with sinonasal teratocarcinosarcoma in the nasal cavity and ethmoid sinus.
Eur Arch Otorhinolaryngol. 2006 Jun;263(6):586-91. doi: 10.1007/s00405-006-0014-1. Epub 2006 Mar 14.
9
Sinonasal teratocarcinosarcoma: a case report and literature review.
J Int Med Res. 2020 Dec;48(12):300060520971488. doi: 10.1177/0300060520971488.
10
A case report of sinonasal teratocarcinosarcoma.
Tohoku J Exp Med. 2000 Jan;190(1):51-9. doi: 10.1620/tjem.190.51.

引用本文的文献

2
Teratocarcinosarcoma of the nasal cavity: challenges in the clinico-pathologic perspectives.
Eur Arch Otorhinolaryngol. 2025 May;282(5):2745-2751. doi: 10.1007/s00405-024-09154-2. Epub 2024 Dec 26.
3
5
Diagnostic and Treatment-Related Challenges in Sinonasal Teratocarcinosarcoma: A Report of Three Cases.
Case Rep Otolaryngol. 2023 Nov 11;2023:4788617. doi: 10.1155/2023/4788617. eCollection 2023.
6
Teratocarcinosarcoma of the head and neck: Clinicopathologic review of a rare entity.
Rare Tumors. 2023 Sep 21;15:20363613231204047. doi: 10.1177/20363613231204047. eCollection 2023.
7
Top 10 Significant Spindled Head and Neck Lesions to Scrutinze.
Head Neck Pathol. 2023 Mar;17(1):132-142. doi: 10.1007/s12105-023-01535-z. Epub 2023 Mar 16.
8
Top 10 Basaloid Neoplasms of the Sinonasal Tract.
Head Neck Pathol. 2023 Mar;17(1):16-32. doi: 10.1007/s12105-022-01508-8. Epub 2023 Mar 16.
9
Multimodality management of sinonasal teratocarcinosarcoma in a 76-year-old Alaska Native female during the COVID-19 pandemic.
Clin Case Rep. 2022 Mar 26;10(3):e05635. doi: 10.1002/ccr3.5635. eCollection 2022 Mar.

本文引用的文献

1
Recurrent Loss of SMARCA4 in Sinonasal Teratocarcinosarcoma.
Am J Surg Pathol. 2020 Oct;44(10):1331-1339. doi: 10.1097/PAS.0000000000001508.
6
Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation.
J Neurol Surg B Skull Base. 2017 Aug;78(4):346-352. doi: 10.1055/s-0037-1601320. Epub 2017 Mar 27.
7
Usefulness of NKX2.2 Immunohistochemistry for Distinguishing Ewing Sarcoma from Other Sinonasal Small Round Blue Cell Tumors.
Head Neck Pathol. 2018 Mar;12(1):89-94. doi: 10.1007/s12105-017-0830-1. Epub 2017 Jun 14.
10
SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Clin Cancer Res. 2016 May 15;22(10):2396-404. doi: 10.1158/1078-0432.CCR-15-1468. Epub 2015 Dec 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验